Last chance to buy GlaxoSmithKline plc for under £16?

Is now the perfect time to buy a stake in GlaxoSmithKline plc (LON:GSK)?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) has endured five tough years, with patents expiring on a number of its big money-spinners and competition from generics. However, the overall trend of its share price has been generally upwards since late 2015, as the market has begun to look ahead to a brighter future of top- and bottom-line growth.

The shares have taken a dip from near £17 in March to around £15.50 today. Is this the last chance to buy a slice of the business for under £16? I can see two scenarios, both of which persuade me that the shares are excellent value at their current level.

Scenario #1

Glaxo’s Q1 results this week — the first to be presented by new chief executive Emma Walmsley — showed rising sales across all three of the group’s businesses: namely, pharmaceuticals (which includes the fast-growing HIV division), consumer healthcare and vaccines.

This diversified model is the legacy of former boss Andrew Witty, and many investors appreciate it because the steady revenues from the consumer business provide a counterbalance to the slightly more lumpy sales (and discovery) of drugs. The group is in good shape, with Ms Walmsley reiterating previous guidance of annual earnings growth in mid-to-high single digits through to 2020.

Analysts’ forecast earnings for the current year give a price-to-earnings (P/E) ratio of 14. This looks cheap to me, in view of the company’s medium-term guidance on earnings growth and a dividend yield of over 5% on top. All things being equal, I would expect the shares to continue their overall upward trajectory, as the market further warms to the group’s prospects.

On the question of whether this is the last chance to buy the shares at under £16, it’s perhaps worth noting that even if the price were to remain at its current £15.50 for the next 12 months, the value of your investment would have advanced to £16.30 due to the juicy 80p dividend.

Scenario #2

Despite the bright future of Glaxo’s diversified business model, some investors are convinced that returns for shareholders could be even better, if the company followed an altogether different strategy. Last year, a number of major shareholders — including celebrated fund manager Neil Woodford — called on Mr Witty to break up the group.

They argued that the sum of the parts was worth significantly more than the whole. Woodford and his team wrote: “All four of Glaxo’s major component businesses could be FTSE 100 companies in their own right, and we strongly believe that any future break-up would unlock considerable shareholder value”.

Mr Witty resisted the calls and new boss Ms Walmsley indicated this week that she was “committed” to the group’s existing structure. However, it’s early days in her tenure and I wouldn’t be surprised if further down the line there is corporate activity — whether demergers or sales — that realise value for shareholders well in excess of £16 a share.

In summary, whatever Glaxo’s future direction, I believe the shares represent excellent value at their current level.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

2 recession-resistant UK stocks I’d buy and hold for a decade!

Our writer details two UK stocks she believes could still continue to perform well in a recession and not feel…

Read more »

Back view of blue NIO EP9 electric vehicle
Investing Articles

Down 31% this year! Is now the moment to buy NIO stock?

NIO stock has moved sharply downwards in the past couple of months. Christopher Ruane likes the business potential -- but…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 dividend stocks I reckon could grow payouts for years to come!

This Fool is looking for dividend stocks and explains why these two picks could be primed to grow their payouts…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Should I buy, sell, or hold my Rolls-Royce shares at £3.50?

This Fool considers what he should do with his Rolls-Royce shares following the FTSE 100 company's excellent full-year results last…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

With a spare £280, here’s how I’d start buying shares this March

Our writer reflects on what he has learnt on the stock market to explain how he would start buying shares…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Are these expensive FTSE 100 stocks actually brilliant bargains?

Paul Summers takes a closer look at two FTSE 100 stocks that could recover strongly in time, despite already carrying…

Read more »

Investing Articles

What might the recent Aviva share price performance tell me as an investor?

Christopher Ruane looks at how the Aviva share price has performed over the past 12 months and considers whether he…

Read more »

Investing Articles

Down by a quarter, is the BT share price a steal?

The BT share price has more than halved in the past five years. What is holding it down -- and…

Read more »